Jun-Young Lee
Corporate Officer/Principal at SAMSUNG ELECTRONICS CO., LTD.
Profile
Jun-Young Lee is currently the Chief Executive Officer at Selecxine, Inc. Co Ltd.
and the Vice President & Head-Visual Display Purchasing at Samsung Electronics Co., Ltd.
He completed his undergraduate degree at Soongsil University.
Jun-Young Lee active positions
| Companies | Position | Start |
|---|---|---|
| SAMSUNG ELECTRONICS CO., LTD. | Corporate Officer/Principal | - |
Selecxine, Inc. Co Ltd.
 Selecxine, Inc. Co Ltd. BiotechnologyHealth Technology Selecxine, Inc. Co Ltd. is a bio start-up founded in December 2018 in an undisclosed location. The company is based in Seoul, South Korea. The South Korean company specializes in developing monoclonal antibodies using platform technology. Selecxine develops antibodies that bind to specific epitopes on target proteins for modification and amplification of the desired signal from bifunctional biomolecules such as cytokines and cytokine receptors. The company's novel candidate, SLC-3010, is an immune-mediated anti-cancer therapeutic that selectively stimulates anti-tumor immune response. The efficacy of SLC-3010 in eradicating various types of tumors was thoroughly demonstrated through various in vitro and in vivo experiments. Selecxine is actively developing subsequent pipelines based on the well-established in-house platform. The company was founded in 2018, and the CEO is Jun-Young Lee. | Chief Executive Officer | - |
Training of Jun-Young Lee
| Soongsil University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SAMSUNG ELECTRONICS CO., LTD. | Electronic Technology |
| Private companies | 1 |
|---|---|
Selecxine, Inc. Co Ltd.
Selecxine, Inc. Co Ltd. BiotechnologyHealth Technology Selecxine, Inc. Co Ltd. is a bio start-up founded in December 2018 in an undisclosed location. The company is based in Seoul, South Korea. The South Korean company specializes in developing monoclonal antibodies using platform technology. Selecxine develops antibodies that bind to specific epitopes on target proteins for modification and amplification of the desired signal from bifunctional biomolecules such as cytokines and cytokine receptors. The company's novel candidate, SLC-3010, is an immune-mediated anti-cancer therapeutic that selectively stimulates anti-tumor immune response. The efficacy of SLC-3010 in eradicating various types of tumors was thoroughly demonstrated through various in vitro and in vivo experiments. Selecxine is actively developing subsequent pipelines based on the well-established in-house platform. The company was founded in 2018, and the CEO is Jun-Young Lee. | Health Technology |
- Stock Market
- Insiders
- Jun-Young Lee
